Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, appointed Carlos Martin as Chief Commercial Officer (CCO). 

With Martin’s appointment, Neurvati reinforces its model as a neuroscience company built for impact: bridging rigorous science with the scientific, operational, and commercial expertise required to deliver breakthroughs to patients globally.

Martin brings over 20 years of leadership experience across global biopharmaceutical markets, with a proven record of building commercial organizations, launching transformative therapies, and strengthening pipeline valuation in highly innovative areas such as gene therapy, radiopharma, oncology, cardiology, and rare diseases.

Martin most recently served as Chief Commercial Officer at Rocket Pharmaceuticals, where he oversaw the company’s transition from a clinical-stage biotech to a commercial-ready organization in gene therapies. There, he developed the company’s U.S., EU, and Japan commercialization strategies and go-to-market models. This included infrastructure and secured pre-launch payer agreements – all designed to accelerate market entry while bolstering investor confidence and company value. 

Earlier in his career, Martin held senior leadership roles at Novartis Pharmaceuticals. At Advanced Accelerator Applications (a Novartis company), he established the radiopharma commercial business in the U.S. at Novartis Oncology. Additionally, he was the Novartis Oncology country head in Chile, where he built a new business unit.

“Carlos brings exactly the kind of experience Neurvati needs at this moment,” said Bruce Leuchter, M.D., President & CEO of Neurvati. “He has repeatedly built commercial organizations in innovative therapeutic areas and modalities. From large markets in oncology and cardiology, including neurology rare diseases, he has successfully translated clinical data into market value and led teams that deliver growth on a global scale. At Neurvati, his leadership will ensure that our transformational scientific advances are properly translated to the market and that our therapies are commercially and operationally prepared to succeed in the future.”